<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385551</url>
  </required_header>
  <id_info>
    <org_study_id>IP-AVV2017</org_study_id>
    <nct_id>NCT03385551</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Estradiol Vaginal Tablets vs Promestriene Vaginal Cream</brief_title>
  <official_title>Observational Study to Evaluate the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the acceptability, efficacy and preferences of 10 of estradiol&#xD;
      vaginal tablets vs promestriene vaginal cream&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, prospective, open-label, parallel-group study to evaluate the&#xD;
      acceptability, efficacy, and preferences of postmenopausal women older than 45 between 10&#xD;
      micrograms of estradiol vaginal tablets vs promestriene vaginal cream&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vulvovaginal Symptoms</measure>
    <time_frame>Change from Baseline, at week 4 and at week 12</time_frame>
    <description>Dispareunya, dryness, itching nd burning</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <description>Patients who have been prescribed by the physician within the standard clinical practice 10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <description>Patients who have been prescribed by the physician within the standard clinical practice promestriene 10mg./g vaginal cream. 1 gr. one application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Estradiol or Promestriene depending on the arm</description>
    <arm_group_label>ARM 1</arm_group_label>
    <other_name>Promestriene</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        120 postmenopausal women aged 45 years or older, with one or more moderate to severe&#xD;
        symptoms of vulvovaginal atrophy (dryness, dyspareunia, soreness or irritation)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Postmenopausal women aged 45 years or older. Women will be considered postmenopausal with&#xD;
        more than 12 months since last menstrual period&#xD;
&#xD;
          -  Women who have been prescribed vaginal estradiol tablets or vaginal promestriene&#xD;
             cream· Women who have read and signed the Informed Consent Form&#xD;
&#xD;
          -  Women with an intact uterus&#xD;
&#xD;
          -  One or more vaginal symptoms (dryness, soreness, irritation, dyspareunia) rated as&#xD;
             moderate to severe. Symptoms are moderate if the patient needs a treatment and feels&#xD;
             discomfort. Symptoms are severe if the patient needs a treatment, and feels such a&#xD;
             degree of discomfort that this could severely impact the subject's daily activities&#xD;
&#xD;
          -  In case of doubt, blood estradiol concentration will be determined, and the subject&#xD;
             will only be enrolled if the levels are equal to 30pg./ml. or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who had a known or suspected history of breast carcinoma&#xD;
&#xD;
               -  Estrogen dependent neoplasia. Women with a known, past or suscpected&#xD;
                  Estrogen-dependent malignant tumours such as endormetrial or ovarian cancer&#xD;
&#xD;
               -  Positive or suspicious mammogram results&#xD;
&#xD;
               -  Any systemic malignant disease&#xD;
&#xD;
               -  Hormone therapy treatment (sex hormones or vaginal treatments or steroids) in the&#xD;
                  last three months Women who had abnormal vaginal bleeding or uterine bleeding of&#xD;
                  unknown cause&#xD;
&#xD;
               -  Vaginal infection requiring treatment&#xD;
&#xD;
               -  Previous or current venous thromboembolism (deep venous thrombosis, pulmonary&#xD;
                  embolism) Untreated endometrial hyperplasia Known thrombophilic disorders (e.g.&#xD;
                  protein C, protein S, or antithrombin deficiency) Active or previous arterial&#xD;
                  thromboembolic disease (e.g. angina, myocardial infarction) Acute liver disease,&#xD;
                  or history of liver disease as long as liver function tests have failed to return&#xD;
                  to normal Known Hypersensitivity to the active substances or to any of the&#xD;
                  excipients Porphyria&#xD;
&#xD;
               -  Any serious disease or chronic condition that could interfere with study&#xD;
                  compliance&#xD;
&#xD;
               -  History of thrombolytic disorders&#xD;
&#xD;
               -  Use of vaginal contraceptives (DIU, vaginal ring…)&#xD;
&#xD;
               -  Participation in another clinical trial in the last three months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal Women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Palacios</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS &quot;S Matteo Foundation&quot;</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvovaginal Atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

